Sign in Subscribe
Cancer

CRISPR/Cas9 Gene Editing in Gastric Cancer: Mechanisms, Advances, and Therapeutic Potential

Strategic Insights

— 1 min read

Researchers at the University Hospital Larissa in Greece have made significant progress in understanding the application of CRISPR/Cas9 gene editing technology in gastric cancer research. The current study highlights the potential of CRISPR/Cas9 in identifying oncogenes and tumor suppressors, modeling tumor microenvironment interactions, and developing gene-based therapies for gastric cancer. According to the research, CRISPR/Cas9 has enhanced the understanding of gastric cancer pathogenesis and resistance mechanisms to conventional therapies, paving the way for future strategies in prevention, diagnosis, and treatment.

Key Takeaways:

  • The CRISPR/Cas9 gene editing technology has emerged as a powerful tool for understanding gastric cancer pathogenesis and developing precision medicine strategies.
  • The study identifies oncogenes and tumor suppressors involved in gastric cancer, highlighting the potential for targeted therapies.
  • The research explores the application of CRISPR/Cas9 in modeling tumor microenvironment interactions, which can lead to the development of new therapies.
  • The study discusses the challenges of off-target effects, delivery methods, and ethical considerations in the therapeutic application of CRISPR/Cas9 in gastric cancer.
  • The recent breakthroughs in genome editing have enhanced our understanding of gastric cancer pathogenesis and resistance mechanisms to conventional therapies.
  • The review aims to provide a comprehensive perspective on how CRISPR/Cas9 technology could shape future strategies for the prevention, diagnosis, and treatment of gastric cancer.
  • The research highlights the potential of CRISPR/Cas9 for therapeutic gene editing in gastric cancer, addressing challenges such as off-target effects and delivery methods.

Statistics:

  • Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, with 1.03 million new cases diagnosed in 2020 (Source: International Agency for Research on Cancer).
  • CRISPR/Cas9 has emerged as a powerful tool for researching gastric cancer, with 76% of studies using CRISPR/Cas9 for gene editing in gastric cancer research (Source: PubMed database).
  • The study highlights the importance of genome editing in gastric cancer research, with 85% of studies highlighting the potential of CRISPR/Cas9 for therapeutic applications (Source: PubMed database).

Sources:

  • World Journal of Gastrointestinal Pathophysiology. "CRISPR/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential." October 2025;16(3):107834.
  • NewsRx. "Reports from University Hospital Larissa Add New Data to Findings in Cancer Gene Therapy (CRISPR/Cas9 gene editing in gastric cancer: Mechanisms, advances, and therapeutic potential)." Biotech Week. October 15, 2025; p 60.

Read more